SparingVision appoints Joseph C. Papa as Chairman
SparingVision appoints Joseph C. Papa as Chairman Former Bausch and Lomb Chairman and CEO joins…
Press Release
SparingVision Conference Participation in H1 2023
SparingVision Conference Participation in H1 2023 Paris, January 31, 2023 – SparingVision (“the Company”), a…
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa
SparingVision s lead asset SPVN06 clears IND application in the US for the treatment of…
SparingVision to Participate in Upcoming Scientific and Medical Conferences
SparingVision to Participate in Upcoming Scientific and Medical Conferences Paris, October 25, 2022 – SparingVision…
SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022
SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022…
SparingVision to Highlight Progress of its lead Gene Independent Gene Therapy Programs SPVN06 and SPVN20 at ESGCT Congress
SparingVision to Highlight Progress of its lead Gene Independent Gene Therapy Programs SPVN06 and SPVN20…
SparingVision SparingVision to Participate in Upcoming Investor and Industry Conferences
SparingVision to Participate in Upcoming Investor and Industry Conferences Paris, September 22, 2022 – SparingVision…
SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
SparingVision raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for…
SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022
SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022 Data…
SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022
SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022 Paris, May…